Vaccinated people less likely to develop long Covid, shows UK study

It also found that vaccine effectiveness against most long-Covid symptoms was highest in people aged 60 years and over

UK Covid, Covid-19, Coronavirus, Pandemic, England
File Photo
IANS London
2 min read Last Updated : Feb 16 2022 | 6:51 PM IST

People who are vaccinated are less likely to develop long Covid even if they catch the virus, reveals a rapid review by the UK Health Security Agency (UKHSA).

According to the BBC, the research team looked at the available evidence to date from 15 studies around the world and found that while some who are jabbed catch Covid, vaccines reduce infection risk and illness, including symptoms like fatigue.

Unvaccinated people, who catch Covid and show symptoms of long Covid, do better if they then get vaccinated.

Some of the studies in the review looked at the effect of vaccination given before infection and found that people with Covid, who received two doses of Pfizer, AstraZeneca or Moderna vaccines or one dose of the Janssen vaccine, were about half as likely as people who received one dose or were unvaccinated to develop long Covid symptoms lasting more than 28 days.

It also found that vaccine effectiveness against most long-Covid symptoms was highest in people aged 60 years and over.

Others that looked at the effects of vaccines in people who already had long-Covid symptoms found that vaccines may improve rather than worsen Covid symptoms, either immediately or over several weeks.

According to the UKHSA, around 2 per cent of the UK's population have reported symptoms of long Covid, such as fatigue, shortness of breath and muscle or joint pain.

Symptoms like these can last for more than four weeks after the infection, the report said.

People who received two doses of vaccine against Covid are less likely to experience this or will have the symptoms for a shorter time, it added.

--IANS

vc/arm

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :CoronavirusUKCoronavirus Vaccinepublic healthVaccinationWorld Health OrganisationCoronavirus Tests

First Published: Feb 16 2022 | 6:51 PM IST

Next Story